Sunshine Murray, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 67.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $6,150 and has fallen 96.6% since, to $209 in 2025.
Across 128 payments — averaging $88.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$8K
- Medtronic$2K
- Boston Scientific$391
- Caldera Medical, Inc$380
- AbbVie$254
- Astellas Pharma US Inc$217
- plus $617 from 15 others
What the payments were for
- Consulting fees$4,72542%
- Speaking & faculty fees$4234%
- Travel & lodging$1,65815%
- Food & beverage$4,51840%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 30 | $7,680 |
| Medtronic(2 entities) | 21 | $1,818 |
| Boston Scientific | 5 | $391 |
| Caldera Medical, Inc | 8 | $380 |
| AbbVie(2 entities) | 26 | $254 |
| Astellas Pharma US Inc | 13 | $217 |
| Coloplast | 5 | $205 |
| AstraZeneca | 2 | $50 |
| Bluewind Medical | 1 | $50 |
| Urovant Sciences Inc | 3 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| Amgen | 2 | $36 |
| Contura, Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $28 |
| Halozyme Inc | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Blue Earth Diagnostics | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Hollister Incorporated | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$5,504
- Axonics$1,740
- Bulkamid$1,571
- INTERSTIM$1,253
- Desara$285
- Advantage System$142
- ALTIS$134
How this compares
$11,358 in reported general payments places this provider in the 85th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 296 | $206,933 |
| GemtesaVibegron | 252 | $191,393 |
| Estradiol | 401 | $23,208 |
| Solifenacin Succinate | 482 | $21,429 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 98 | $11,710 |
| EstringEstradiol | 18 | $9,543 |
| Mirabegron ErMirabegron | 13 | $7,703 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 268 | $6,978 |
| Trospium Chloride | 92 | $6,923 |
| Trospium Chloride ErTrospium Chloride | 22 | $4,079 |
| Methenamine Hippurate | 36 | $2,153 |
| Tamsulosin Hcl | 129 | $1,944 |
| Tolterodine Tartrate ErTolterodine Tartrate | 47 | $1,584 |
| YuvafemEstradiol | 15 | $1,402 |
| Trimethoprim | 19 | $1,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $217 | $206,933296 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $46 | $191,393252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 145 urology providers in Oklahoma.
Other urology in Tulsa
- Melanie KetchandjiTulsa$111K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Charles PritchardTulsa$23K
- Sean DoyleTulsa$17K
- Joshua VicenaTulsa$16K
- Curtis PowellTulsa$16K
- Wesley BrookoverTulsa$13K
- Thomas RashidTulsa$12K
- Dae KimTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.